Understanding mitotane mode of action

U Waszut1, P Szyszka1, D Dworakowska2,3,4

  • 1Department of Nuclear Medicine, Medical University of Gdansk, Gdansk, Poland.

Insights

Mitotane is a key treatment for adrenocortical carcinoma, selectively targeting adrenal tissue. This review explores its mitochondrial mechanisms, revealing insights into its therapeutic effects and potential for future research.

Area of Science:

  • Biochemistry
  • Oncology
  • Pharmacology

Background:

  • Adrenocortical carcinoma (ACC) is a rare endocrine malignancy with a poor prognosis.
  • Mitotane is the primary therapeutic agent for ACC, particularly in post-operative and inoperable cases.
  • The precise mechanism of mitotane's action remains incompletely understood despite decades of clinical use.

Purpose of the Study:

  • To review current knowledge on mitotane's effects on adrenal tissue and cell lines.
  • To explore the basis for mitotane's selectivity towards adrenal tissue.
  • To focus on the role of mitochondria in mitotane's mechanism of action.

Main Methods:

  • Review of existing literature on mitotane's effects.
  • Analysis of studies on adrenal tissue, primary cell cultures, and cancer cell lines.
  • Examination of mitochondrial function and cellular processes affected by mitotane.

Main Results:

  • Mitotane exhibits selective effects on adrenal tissue, with mitochondria being a primary target.
  • Evidence suggests mitotane activation within mitochondria, impacting energy metabolism and cellular processes.
  • Mitotane influences downstream cellular events, including the initiation of apoptosis.

Conclusions:

  • Mitochondrial mechanisms are central to mitotane's therapeutic effects in adrenocortical carcinoma.
  • Understanding mitotane's impact on mitochondrial function offers avenues for improved ACC treatment strategies.
  • Further genomic and proteomic studies are warranted to fully elucidate mitotane's action.

Related Concept Videos

Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.8K
Electron Transport Chain: Complex I and II01:46

Electron Transport Chain: Complex I and II

The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
19.3K
Drugs that Destabilize Microtubules01:10

Drugs that Destabilize Microtubules

Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
4.2K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
8.2K
Nondepolarizing (Competitive) Neuromuscular Blockers: Pharmacological Actions01:27

Nondepolarizing (Competitive) Neuromuscular Blockers: Pharmacological Actions

Nondepolarizing neuromuscular blockers prevent the membrane depolarization of muscle cells and inhibit muscle contraction. These are usually administered with anesthetics to achieve complete muscle relaxation. Upon administration, these drugs first block the small, rapidly contracting muscles of the face and hands, followed by the larger muscles of the trunk and the intercostal muscles. The diaphragm is the last muscle to be affected.
Although all competitive neuromuscular blockers are designed...
1.1K
Nondepolarizing (Competitive) Neuromuscular Blockers: Mechanism of Action01:17

Nondepolarizing (Competitive) Neuromuscular Blockers: Mechanism of Action

Nondepolarizing neuromuscular blockers induce paralysis by competitively blocking nicotinic acetylcholine receptors at the muscle end plate. Examples include pancuronium, mivacurium, vecuronium, and rocuronium. These quaternary ammonium derivatives are administered intravenously, are poorly absorbed, and are excreted via the kidneys.
Competitive antagonists prevent acetylcholine from binding to its receptor, inhibiting membrane depolarization. Without conformational changes or intrinsic...
3.2K